News tagged with lucentis
Related topics: macular degeneration
Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment (Fab) derived from the same parent mouse antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (ARMD), a common form of age-related vision loss.
Some investigators believe that bevacizumab at an average cost of $42 a dose (in the U.S.) is as effective as ranibizumab at an average cost of $1,593 a dose.
Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts ...
Ophthalmology Feb 12, 2013 | not rated yet | 0
The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international ...
Ophthalmology May 07, 2012 | not rated yet | 0 |
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although ...
Ophthalmology Apr 30, 2012 | not rated yet | 1
(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).
Medications Apr 24, 2012 | 1 / 5 (1) | 0
(AP) -- Regulators on Friday approved Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat a common cause of blindness in older people.
Medications Nov 19, 2011 | 5 / 5 (1) | 5
Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure ...
Diseases, Conditions, Syndromes Oct 24, 2011 | not rated yet | 0
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is ...
Diseases, Conditions, Syndromes Apr 28, 2011 | not rated yet | 0 |